Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Shares Outstanding (Diluted Average) (2019 - 2025)

Historic Shares Outstanding (Diluted Average) for ImmunityBio (IBRX) over the last 7 years, with Q3 2025 value amounting to $946.6 million.

  • ImmunityBio's Shares Outstanding (Diluted Average) rose 3562.38% to $946.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $946.6 million, marking a year-over-year increase of 3562.38%. This contributed to the annual value of $700.4 million for FY2024, which is 3771.01% up from last year.
  • Per ImmunityBio's latest filing, its Shares Outstanding (Diluted Average) stood at $946.6 million for Q3 2025, which was up 3562.38% from $888.2 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Shares Outstanding (Diluted Average) registered a high of $946.6 million during Q3 2025, and its lowest value of $382.7 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $437.5 million (2023), whereas its average is $550.7 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first surged by 209.42% in 2022, then soared by 5706.35% in 2024.
  • ImmunityBio's Shares Outstanding (Diluted Average) (Quarter) stood at $389.2 million in 2021, then rose by 2.74% to $399.9 million in 2022, then increased by 27.19% to $508.6 million in 2023, then surged by 37.71% to $700.4 million in 2024, then soared by 35.14% to $946.6 million in 2025.
  • Its last three reported values are $946.6 million in Q3 2025, $888.2 million for Q2 2025, and $853.2 million during Q1 2025.